Published Studies Related to Medroxyprogesterone
Well-designed clinical trials related to Medroxyprogesterone
Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. [2011.08]
Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. [2011.03.01]
Differential effects of estrogen and micronized progesterone or
medroxyprogesterone acetate on cognition in postmenopausal women. [2011]
Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. [2010.09]
Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial. [2010.08]
Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. [2010.06]
Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy. [2010.05]
Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. [2010.02]
Cardiovascular and metabolic effects of medroxyprogesterone acetate versus
conjugated equine estrogen after premenopausal hysterectomy with bilateral
ovariectomy. [2010]
[Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis] [2009.07]
Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. [2009.04]
Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. [2009.01]
Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. [2009]
Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. [2008.09]
Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. [2008.05]
Synchronization of follicular wave emergence in the seasonally anestrous ewe: the effects of estradiol with or without medroxyprogesterone acetate. [2008.04.15]
Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women. [2008.04]
Association between caffeine intake and bone mass among young women: potential effect modification by depot medroxyprogesterone acetate use. [2008.04]
Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: a randomized, prospective, controlled clinical trial in female smokers. [2008]
The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors. [2008]
Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. [2007.12.21]
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. [2007.12.01]
Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis : results of a randomized controlled trial. [2007.10.11]
A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature. [2007.10]
Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. [2007.08]
Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. [2007.06]
Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. [2007.05]
Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. [2007.03]
Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. [2007.01]
[Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol] [2007]
Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. [2006.11]
Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. [2006.11]
Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. [2006.10]
Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. [2006.10]
Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. [2006.09]
Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. [2006.06]
Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7. [2006.03.20]
The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. [2006.03]
Effects of mifepristone on proliferation and apoptosis of human endometrium in new users of medroxyprogesterone acetate. [2006.03]
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma. [2006.02.20]
Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women. [2006.02.20]
Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. [2006.02]
Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. [2006.01]
Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia menopause (PAM) study. [2005.11]
Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women. [2005.10]
Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. [2005.09.16]
Randomized assignment to copper IUD or depot-medroxyprogesterone acetate: feasibility of enrollment, continuation and disease ascertainment. [2005.09]
Concentration of depot medroxyprogesterone acetate and pain scores in adolescents: a randomized clinical trial. [2005.08]
Effect on sexual life--a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate. [2005.04]
Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. [2005.04]
In vivo assessment of the regulation of transforming growth factor alpha, epidermal growth factor (EGF), and EGF receptor in the human endometrium by medroxyprogesterone acetate. [2005.01]
Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. [2005.01]
Well-designed clinical trials possibly related to Medroxyprogesterone
Estrogen plus progestin and colorectal cancer incidence and mortality. [2012]
Breast cancer risk during hormone therapy: experimental versus clinical data. [2012]
Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. [2011.10.05]
Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. [2011.10]
Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy. [2011.09.19]
Steroidal contraceptives: effect on bone fractures in women. [2011.07.06]
The effects of selective estrogen receptor modulator treatment following hormone replacement therapy on elderly postmenopausal women with osteoporosis. [2011.05.31]
Strategies to improve adherence and acceptability of hormonal methods of contraception. [2011.04.13]
Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. [2011]
Beneficial influence of postmenopausal estrogen therapy on serum adhesion molecules is independent of the route and dose of administration. [2011]
Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. [2010.12]
The effects of a low therapeutic dose of betaCG fragment-lytic peptide conjugates on ovarian function and gonadotropin secretion in ewes: a randomized controlled trial. [2010.11]
Clinical trials in male hormonal contraception. [2010.11]
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. [2010.10.20]
Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. [2010.10.11]
Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy. [2010.10]
Vaginal estrogen supplementation during Depo-Provera initiation: a randomized controlled trial. [2010.09]
Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. [2010.07]
Estimating absolute risks in the presence of nonadherence: an application to a follow-up study with baseline randomization. [2010.07]
Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy. [2010.07]
Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. [2010.06.24]
Copper containing intra-uterine devices versus depot progestogens for contraception. [2010.06.16]
Effectiveness of hormone therapy for treating dry eye syndrome in postmenopausal women: a randomized trial. [2010.06]
Effects of estrogen plus progesterone on hemodynamic and vascular reactivity in hypertensive postmenopausal women. [2010.06]
Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women. [2010.06]
Effect of dienogest on estrogen-induced nitric oxide production in human umbilical vein endothelial cells and endothelium-dependent vasodilatation in postmenopausal women. [2010.05]
The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women. [2010.05]
Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. [2010.04]
[Effects of Kuntai Capsule and hormone replacement therapy on cognitive function and mental symptoms of early postmenopausal women: a randomized controlled trial] [2010.04]
Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. [2010.04]
Hormone therapy and physical function change among older women in the Women's Health Initiative: a randomized controlled trial. [2010.03]
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. [2010.02.16]
Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women. [2010.02]
Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin. [2010.01]
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. [2010]
Striking increases in carotid artery wall thickness in healthy subjects. [2010]
Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive
women: A placebo-controlled trial on post-menopausal hormone therapy. [2010]
Submaximal exercise coronary artery flow increases in postmenopausal women
without coronary artery disease after estrogen and atorvastatin. [2010]
Menopausal hormone therapy, hormone receptor status, and lung cancer in women. [2009.12]
Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. [2009.12]
Brain volumes, cognitive impairment, and conjugated equine estrogens. [2009.12]
Hormone therapy and cognitive function. [2009.11]
Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. [2009.11]
Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. [2009.11]
Effects of botanicals and combined hormone therapy on cognition in postmenopausal women. [2009.11]
Effect of hot flushes on vascular function: a randomized controlled trial. [2009.10]
Growth hormone and sex steroid effects on serum glucose, insulin, and lipid concentrations in healthy older women and men. [2009.10]
Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. [2009.09.01]
Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. [2009.07.15]
|
